Leora Horn

17.4k total citations · 4 hit papers
147 papers, 6.5k citations indexed

About

Leora Horn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Leora Horn has authored 147 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 90 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Leora Horn's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (66 papers) and Cancer therapeutics and mechanisms (28 papers). Leora Horn is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (66 papers) and Cancer therapeutics and mechanisms (28 papers). Leora Horn collaborates with scholars based in United States, Germany and Spain. Leora Horn's co-authors include Myung‐Ju Ahn, Suresh S. Ramalingam, Enriqueta Felip, Yuichiro Ohe, Sang-We Kim, James Chih‐Hsin Yang, Dong‐Wan Kim, Pasi A. Jänne, Wade T. Iams and Mireille Cantarini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Leora Horn

142 papers receiving 6.4k citations

Hit Papers

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung C... 2015 2026 2018 2022 2015 2021 2016 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
    2015 1.6k citations Myung‐Ju Ahn, Sang-We Kim et al. profile →
  2. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
    2021 484 citations Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology profile →
  3. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
  4. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 303 citations Geoffrey R. Oxnard, Helena A. Yu et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leora Horn United States 37 4.7k 3.5k 2.0k 1.4k 1.0k 147 6.5k
Francesco Perrone Italy 38 3.6k 0.8× 1.8k 0.5× 1.1k 0.5× 698 0.5× 870 0.9× 188 5.9k
Mitchell C. Posner United States 43 2.9k 0.6× 2.5k 0.7× 1.0k 0.5× 621 0.5× 856 0.8× 175 6.4k
Raffaele Califano United Kingdom 28 3.3k 0.7× 2.5k 0.7× 1.1k 0.5× 821 0.6× 682 0.7× 118 4.5k
Dara L. Aisner United States 51 3.7k 0.8× 4.8k 1.4× 3.5k 1.7× 476 0.3× 1.8k 1.8× 134 8.5k
Joan Palou Spain 44 2.0k 0.4× 2.3k 0.6× 1.8k 0.9× 702 0.5× 682 0.7× 300 12.0k
Manuel Modiano United States 25 5.0k 1.1× 1.8k 0.5× 1.6k 0.8× 1.3k 0.9× 1.7k 1.7× 87 7.0k
Robert L. Comis United States 41 3.4k 0.7× 2.1k 0.6× 1.3k 0.6× 1.1k 0.8× 492 0.5× 137 5.6k
Esther Bastiaannet Netherlands 45 4.5k 0.9× 1.6k 0.4× 847 0.4× 566 0.4× 1.8k 1.7× 263 6.9k
Jyoti D. Patel United States 38 3.9k 0.8× 3.4k 1.0× 1.4k 0.7× 375 0.3× 832 0.8× 230 6.1k
Stephen Falk United Kingdom 38 4.9k 1.0× 7.7k 2.2× 840 0.4× 613 0.4× 870 0.9× 123 11.4k

Countries citing papers authored by Leora Horn

Since Specialization
Citations

This map shows the geographic impact of Leora Horn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leora Horn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leora Horn more than expected).

Fields of papers citing papers by Leora Horn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leora Horn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leora Horn. The network helps show where Leora Horn may publish in the future.

Co-authorship network of co-authors of Leora Horn

This figure shows the co-authorship network connecting the top 25 collaborators of Leora Horn. A scholar is included among the top collaborators of Leora Horn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leora Horn. Leora Horn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gerber, David E., Tanushree Prasad, Song Zhang, et al.. (2025). Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials. Clinical Cancer Research. 31(6). 1103–1108. 1 indexed citations
2.
3.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8597–8597. 1 indexed citations
4.
Itzstein, Mitchell S. von, Timothy F. Burns, Jonathan E. Dowell, et al.. (2024). Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 31(4). 639–648. 1 indexed citations
5.
Abbosh, Chris, Darren Hodgson, Gary J. Doherty, et al.. (2024). Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends in cancer. 10(7). 643–654. 18 indexed citations
6.
Liu, Stephen V., Martin Reck, Aaron S. Mansfield, et al.. (2021). Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology. 39(6). 619–630. 484 indexed citations breakdown →
7.
Wakelee, Heather A., Karen L. Reckamp, Ticiana Leal, et al.. (2019). P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. Journal of Thoracic Oncology. 14(10). S566–S566. 2 indexed citations
8.
McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations
9.
10.
Goldberg, Sarah B., Mary W. Redman, Rogério Lilenbaum, et al.. (2018). OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403. Journal of Thoracic Oncology. 13(10). S343–S344. 5 indexed citations
11.
Yu, Helena A., Alexander I. Spira, Leora Horn, et al.. (2017). A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clinical Cancer Research. 23(24). 7467–7473. 23 indexed citations
12.
Gadgeel, Shirish M., Adrienne Johnson, Leora Horn, et al.. (2017). P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling. Journal of Thoracic Oncology. 12(1). S1286–S1286. 1 indexed citations
13.
Goldberg, Sarah B., James Moon, Rogério Lilenbaum, et al.. (2017). P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403. Journal of Thoracic Oncology. 12(1). S1220–S1221. 1 indexed citations
14.
Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →
15.
Wakelee, Heather A., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology. 11(10). S209–S210. 3 indexed citations
16.
Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 11(11). S256–S257. 7 indexed citations
17.
Horn, Leora, Martin Reck, Tony Mok, et al.. (2016). PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(11). S305–S306. 3 indexed citations
18.
Shanafelt, Tait D., Marilyn Raymond, Leora Horn, et al.. (2014). Oncology Fellows' Career Plans, Expectations, and Well-Being: Do Fellows Know What They Are Getting Into?. Journal of Clinical Oncology. 32(27). 2991–2997. 46 indexed citations
19.
20.
Horn, Leora, Vicki L. Keedy, Norma Campbell, et al.. (2012). Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials. Clinical Lung Cancer. 14(1). 14–18. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Perrone Breakdown of academic impact, for papers by Mitchell C. Posner Breakdown of academic impact, for papers by Raffaele Califano Breakdown of academic impact, for papers by Dara L. Aisner Breakdown of academic impact, for papers by Joan Palou Breakdown of academic impact, for papers by Manuel Modiano Breakdown of academic impact, for papers by Robert L. Comis Breakdown of academic impact, for papers by Esther Bastiaannet Breakdown of academic impact, for papers by Jyoti D. Patel Breakdown of academic impact, for papers by Stephen Falk
Rankless by CCL
2026